Atara Biotherapeutics 2024 Cell Therapy Cancer Autoimmune

Atara Biotherapeutics presented an overview of its allogeneic CAR T cell immunotherapy platform designed to treat cancer and autoimmune diseases. The company, founded in 2012 and headquartered in Thousand Oaks, CA, leverages off-the-shelf EBV T cell technology with selective CAR addition for hematological malignancies and B-cell autoimmune conditions including lupus nephritis.